Scott N. Boyle - Feb 13, 2025 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Business Officer
Signature
/s/ Shagha Russell, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Feb 13, 2025
Transactions value $
-$16,733
Form type
4
Date filed
2/18/2025, 04:55 PM
Previous filing
Nov 12, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Tax liability -$5.55K -1.74K -3.07% $3.20 54.8K Feb 13, 2025 Direct F1
transaction CCCC Common Stock Award $0 +56.5K +103.04% $0.00 111K Feb 14, 2025 Direct F2
transaction CCCC Common Stock Sale -$1.54K -490 -0.44% $3.15 111K Feb 14, 2025 Direct F3
transaction CCCC Common Stock Tax liability -$7.53K -2.37K -2.14% $3.18 108K Feb 14, 2025 Direct F1
transaction CCCC Common Stock Sale -$2.11K -669 -0.62% $3.15 108K Feb 18, 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Award $0 +84.7K $0.00 84.7K Feb 14, 2025 Common Stock 84.7K $3.18 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person.
F2 Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2026.
F3 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2024.
F4 The shares underlying this option shall vest and become exercisable in forty-eight equal monthly installments following the grant date, with the first installment vesting on March 14, 2025.